. Author manuscript; available in PMC: 2017 Jul 14.

Published in final edited form as: Aliment Pharmacol Ther. 2014 May 11;40(1):93–104. doi: 10.1111/apt.12788

Table 1.

Baseline Patient Characteristics

N	13

Age (years)^*	42 (18–58)

Male Gender	11 (85%)

Race (Caucasian/African-American)	11/2

Estimated duration of disease (years)^*	25 (7–35)

Infection Source¹
IV Drug Abuse	6 (46%)
Sexual	2 (15%)
Transfusion	2 (15%)
Endemic Region	5 (39%)

ALT (U/L)^*	141 (31–506)

HDV-RNA (Log₁₀ Genome Equivalent/mL)^*	6.7±1.2

HBsAg (Log₁₀ IU/mL)^*	3.7±0.6

HBV-DNA < 100 IU/mL	6 (46%)

HBV-DNA (Log₁₀ IU/mL)^* ²	2.9 (2–4.9)

Fibrosis (median, range) (Ishak score)	3 (3–6)

HVPG (mmHg)^*	11 (4–25)

More than one suspected source possible

Limited to patients with HBV-DNA > 100 IU/ml

Mean (range)